These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8458338)

  • 1. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides.
    Offensperger WB; Offensperger S; Walter E; Teubner K; Igloi G; Blum HE; Gerok W
    EMBO J; 1993 Mar; 12(3):1257-62. PubMed ID: 8458338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress and Prospects of Anti-HBV Gene Therapy Development.
    Maepa MB; Roelofse I; Ely A; Arbuthnot P
    Int J Mol Sci; 2015 Jul; 16(8):17589-610. PubMed ID: 26263978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene therapeutic approaches to inhibit hepatitis B virus replication.
    Gebbing M; Bergmann T; Schulz E; Ehrhardt A
    World J Hepatol; 2015 Feb; 7(2):150-64. PubMed ID: 25729471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocytes targeting of cationic liposomes modified with soybean sterylglucoside and polyethylene glycol.
    Qi XR; Yan WW; Shi J
    World J Gastroenterol; 2005 Aug; 11(32):4947-52. PubMed ID: 16124043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translation of stable hepadnaviral mRNA cleavage fragments induced by the action of phosphorothioate-modified antisense oligodeoxynucleotides.
    Hasselblatt P; Hockenjos B; Thoma C; Blum HE; Offensperger WB
    Nucleic Acids Res; 2005; 33(1):114-25. PubMed ID: 15640448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific inhibition of coxsackievirus B3 translation and replication by phosphorothioate antisense oligodeoxynucleotides.
    Wang A; Cheung PK; Zhang H; Carthy CM; Bohunek L; Wilson JE; McManus BM; Yang D
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1043-52. PubMed ID: 11257014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular strategies for interrupting arthropod-borne virus transmission by mosquitoes.
    Blair CD; Adelman ZN; Olson KE
    Clin Microbiol Rev; 2000 Oct; 13(4):651-61. PubMed ID: 11023962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target site search and effective inhibition of leukaemic cell growth by a covalently closed multiple anti-sense oligonucleotide to c-myb.
    Moon IJ; Lee Y; Kwak CS; Lee JH; Choi K; Schreiber AD; Park JG
    Biochem J; 2000 Mar; 346 Pt 2(Pt 2):295-303. PubMed ID: 10677346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene therapy of hepatic diseases: prospects for the new millennium.
    Shetty K; Wu GY; Wu CH
    Gut; 2000 Jan; 46(1):136-9. PubMed ID: 10601070
    [No Abstract]   [Full Text] [Related]  

  • 10. Preclinical and clinical pharmacology of antisense oligonucleotides.
    Marcusson EG; Yacyshyn BR; Shanahan WR; Dean NM
    Mol Biotechnol; 1999 Aug; 12(1):1-11. PubMed ID: 10554769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotide inhibition of hepatitis C virus (HCV) gene expression in livers of mice infected with an HCV-vaccinia virus recombinant.
    Zhang H; Hanecak R; Brown-Driver V; Azad R; Conklin B; Fox MC; Anderson KP
    Antimicrob Agents Chemother; 1999 Feb; 43(2):347-53. PubMed ID: 9925530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies.
    Lorenz P; Baker BF; Bennett CF; Spector DL
    Mol Biol Cell; 1998 May; 9(5):1007-23. PubMed ID: 9571236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for infectious diseases.
    Bunnell BA; Morgan RA
    Clin Microbiol Rev; 1998 Jan; 11(1):42-56. PubMed ID: 9457428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense inhibition of virus infections.
    Kilkuskie RE; Field AK
    Adv Pharmacol; 1997; 40():437-83. PubMed ID: 9217933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro inhibition of hepatitis C virus gene expression by chemically modified antisense oligodeoxynucleotides.
    Vidalin O; Major ME; Rayner B; Imbach JL; Trépo C; Inchauspé G
    Antimicrob Agents Chemother; 1996 Oct; 40(10):2337-44. PubMed ID: 8891141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting hepatitis B therapy to the liver. Clinical pharmacokinetic considerations.
    Rensen PC; de Vrueh RL; van Berkel TJ
    Clin Pharmacokinet; 1996 Aug; 31(2):131-55. PubMed ID: 8853935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivo.
    Hafkemeyer P; Keppler-Hafkemeyer A; al Haya MA; von Janta-Lipinski M; Matthes E; Lehmann C; Offensperger WB; Offensperger S; Gerok W; Blum HE
    Antimicrob Agents Chemother; 1996 Mar; 40(3):792-4. PubMed ID: 8851615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin.
    Hartmann G; Krug A; Waller-Fontaine K; Endres S
    Mol Med; 1996 Jul; 2(4):429-38. PubMed ID: 8827713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triplex-forming oligonucleotides trigger conformation changes of a target hairpin sequence.
    Brossalina E; Demchenko E; Demchenko Y; Vlassov V; Toulmé JJ
    Nucleic Acids Res; 1996 Sep; 24(17):3392-8. PubMed ID: 8811094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy in gastroenterology.
    Pandha HS; Lemoine NR
    Gut; 1996 Feb; 38(2):161-5. PubMed ID: 8801190
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.